Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 26:16:1563303.
doi: 10.3389/fimmu.2025.1563303. eCollection 2025.

Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives

Affiliations
Review

Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives

Xuan-Yu Gu et al. Front Immunol. .

Abstract

Lactate has emerged as a key regulator in the tumor microenvironment (TME), influencing both tumor progression and immune dynamics. As a byproduct of aerobic glycolysis, lactate satisfies the metabolic needs of proliferating tumor cells while reshaping the TME to facilitate immune evasion. Elevated lactate levels inhibit effector immune cells such as CD8+ T and natural killer cells, while supporting immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, thus fostering an immunosuppressive environment. Lactate promotes epigenetic reprogramming, stabilizes hypoxia-inducible factor-1α, and activates nuclear factor kappa B, leading to further immunological dysfunction. In this review, we examined the role of lactate in metabolic reprogramming, immune suppression, and treatment resistance. We also discuss promising therapeutic strategies targeting lactate metabolism, including lactate dehydrogenase inhibitors, monocarboxylate transporter inhibitors, and TME neutralization methods, all of which can restore immune function and enhance immunotherapy outcomes. By highlighting recent advances, this review provides a theoretical foundation for integrating lactate-targeted therapies into clinical practice. We also highlight the potential synergy between these therapies and current immunotherapeutic strategies, providing new avenues for addressing TME-related challenges and improving outcomes for patients with cancer.

Keywords: immunosuppression; immunotherapy; lactate metabolism; targeted therapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Dual role of lactate in the tumor microenvironment: Metabolic regulation and immunosuppression.
Figure 2
Figure 2
Lactate-mediated crosstalk: bridging metabolism, epigenetics, and immune regulation in the tumor microenvironment. lactate, as a major mediator, connects cellular metabolism, transcriptional control, and immunological signaling networks in the TME. Lactate enters cells through MCT1 and upregulates MOESIN, stimulating the TGF-β/STAT3 pathway to enhance Treg cell development and immunological suppression. Lactate regulates HIF-1α stability, VEGF, and PD-L1 expression, facilitating immune evasion. In the epigenetic landscape, METTL3 promotes gene transcription through m6A RNA alterations, whereas p300 acetylates histones (Kla), hence increasing transcriptional activity. These interrelated pathways govern the TME by balancing M1 and M2 macrophage polarization, as well as directing immunological homeostasis and tumor growth. The pathways shown represent select examples of lactate’s downstream effects on immune modulation. TME, tumor microenvironment; MCT, monocarboxylate transporters; VEGF, vascular endothelial growth factor; PD-L1, programmed death ligand 1.

Similar articles

Cited by

References

    1. Zhang W, Wang C, Hu X, Lian Y, Ding C, Ming L. Inhibition of LDHA suppresses cell proliferation and increases mitochondrial apoptosis via the JNK signaling pathway in cervical cancer cells. Oncol Rep. (2022) 47(4):77. doi: 10.3892/or.2022.8288 - DOI - PMC - PubMed
    1. Wen L, Han Z, Li J, Du Y. c-MYC and HIF1α promoter G-quadruplexes dependent metabolic regulation mechanism of berberine in colon cancer. J Gastrointest Oncol. (2022) 13:1152–68. doi: 10.21037/jgo-22-389 - DOI - PMC - PubMed
    1. Duan Q, Zhang S, Wang Y, Lu D, Sun Y, Wu Y. Proton-coupled monocarboxylate transporters in cancer: From metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications. Front Cell Dev Biol. (2022) 10:1069555. doi: 10.3389/fcell.2022.1069555 - DOI - PMC - PubMed
    1. Boidot R, Végran F, Meulle A, Le Breton A, Dessy C, Sonveaux P, et al. . Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. (2012) 72:939–48. doi: 10.1158/0008-5472.CAN-11-2474 - DOI - PubMed
    1. Rahman MA, Yadab MK, Ali MM. Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy. Cells. (2024) 13(22):1924. doi: 10.3390/cells13221924 - DOI - PMC - PubMed